An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency - PubMed (original) (raw)
An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency
Ta-Chiang Liu et al. Mol Ther. 2004 Jun.
Free article
Abstract
Oncolytic adenoviruses hold promise as a new treatment platform for cancer, but limitations have been identified, including limited spread and potency. The adenoviral protein E1B-19 kDa is a Bcl-2 homologue that blocks apoptosis induction via the intrinsic and extrinsic pathways, specifically including tumor necrosis factor-mediated cell death. We demonstrate that an E1B-19 kDa gene deletion mutant had tumor necrosis factor-enhanced cancer selectivity, in vitro and in vivo, due to genetic blocks in apoptosis pathways in cancer cells. In addition, this mutant demonstrated significantly enhanced viral spread and antitumoral potency relative to dl1520 (aka Onyx-015) and wild-type adenovirus in vitro. Significant antitumoral efficacy was demonstrated in vivo by intratumoral and intravenous routes of administration. E1B-19 kDa deletion should be considered as a feature of oncolytic adenoviruses to enhance their safety, spread, and efficacy.
Similar articles
- Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D. Liu TC, et al. Gene Ther. 2005 Sep;12(17):1333-46. doi: 10.1038/sj.gt.3302555. Gene Ther. 2005. PMID: 15920462 - E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M, Abei M, Kawashima R, Seo E, Fukuda K, Ugai H, Murata T, Tanaka N, Hyodo I, Hamada H, Yokoyama KK. Wakayama M, et al. Clin Cancer Res. 2007 May 15;13(10):3043-50. doi: 10.1158/1078-0432.CCR-06-2103. Clin Cancer Res. 2007. PMID: 17505007 - E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J, Kim JH, Choi KJ, Kim PH, Yun CO. Kim J, et al. Hum Gene Ther. 2007 Sep;18(9):773-86. doi: 10.1089/hum.2006.167. Hum Gene Ther. 2007. PMID: 17725410 - Oncolytic Replication of E1b-Deleted Adenoviruses.
Cheng PH, Wechman SL, McMasters KM, Zhou HS. Cheng PH, et al. Viruses. 2015 Nov 6;7(11):5767-79. doi: 10.3390/v7112905. Viruses. 2015. PMID: 26561828 Free PMC article. Review. - Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.
Kirn D. Kirn D. Oncogene. 2000 Dec 27;19(56):6660-9. doi: 10.1038/sj.onc.1204094. Oncogene. 2000. PMID: 11426652 Review.
Cited by
- Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial.
Ning W, Qian X, Dunmall LC, Liu F, Guo Y, Li S, Song D, Liu D, Ma L, Qu Y, Wang H, Gu C, Zhang M, Wang Y, Wang S, Zhang H. Ning W, et al. Nat Commun. 2024 Nov 8;15(1):9299. doi: 10.1038/s41467-024-53041-7. Nat Commun. 2024. PMID: 39516192 Clinical Trial. - BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Conley AP, Roland CL, Bessudo A, Gastman BR, Villaflor VM, Larson C, Reid TR, Caroen S, Oronsky B, Stirn M, Williams J, Burbano E, Coyle A, Barve MA, Wagle N, Abrouk N, Kesari S. Conley AP, et al. Cancer Gene Ther. 2024 Apr;31(4):517-526. doi: 10.1038/s41417-023-00720-0. Epub 2023 Dec 25. Cancer Gene Ther. 2024. PMID: 38146006 Free PMC article. Clinical Trial. - Oncolytic virotherapy: basic principles, recent advances and future directions.
Lin D, Shen Y, Liang T. Lin D, et al. Signal Transduct Target Ther. 2023 Apr 11;8(1):156. doi: 10.1038/s41392-023-01407-6. Signal Transduct Target Ther. 2023. PMID: 37041165 Free PMC article. Review. - Evaluation of Human Mesenchymal Stromal Cells as Carriers for the Delivery of Oncolytic HAdV-5 to Head and Neck Squamous Cell Carcinomas.
Nilson R, Krutzke L, Wienen F, Rojewski M, Zeplin PH, Funk W, Schrezenmeier H, Kochanek S, Kritzinger A. Nilson R, et al. Viruses. 2023 Jan 13;15(1):218. doi: 10.3390/v15010218. Viruses. 2023. PMID: 36680258 Free PMC article. - Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy.
Omole RK, Oluwatola O, Akere MT, Eniafe J, Agboluaje EO, Daramola OB, Ayantunji YJ, Omotade TI, Torimiro N, Ayilara MS, Adeyemi OI, Salinsile OS. Omole RK, et al. Front Pharmacol. 2022 Dec 8;13:1082797. doi: 10.3389/fphar.2022.1082797. eCollection 2022. Front Pharmacol. 2022. PMID: 36569326 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials